We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Charles River Laboratories has acquired early-stage contract research organization (CRO) Retrogenix, a provider of specialized bioanalytical services utilizing its proprietary cell microarray technology, for $48 million.
UK-based biotechnology company Retrogenix and US-based Resonant Therapeutics, Inc. announced that they have entered into a non-exclusive strategic partnership to ...